Reproducibility in Diabetes Research: What It Means and How We Protect It

What does reproducibility mean in diabetes research?

Reproducibility means that an independent team, given your methods and your data, can run the same analysis and arrive at the same result. Replicability, a close cousin, means a fresh study in a fresh sample reaches the same conclusion. Diabetes research depends on both because the diseases we study are slow, heterogeneous, and shaped by genetics, behavior, and environment at once. A single positive finding is a hypothesis. A finding that holds up when someone else tests it is closer to knowledge. The good news, and the reason I write this hopefully rather than anxiously, is that we already know what protects reproducibility, and most of it is within reach of any honest lab.

I have spent my research life inside this problem. My doctoral work at the Lund University Diabetes Centre sits in the genetics of type 2 diabetes, a field that learned its reproducibility lessons the hard way. My later work in systems medicine at Stanford, with Professor Atul Butte, lives downstream of those lessons, where the question is whether a signal in a large dataset is real or just a pattern the data happened to wear that day.

Why is reproducibility so hard in this field?

Type 2 diabetes is polygenic, which means hundreds of genetic variants each nudge risk by a small amount. In the early years of genetic association studies, labs would test a candidate gene in a modest sample, find a variant that looked linked to disease, and publish. Then a second lab would test the same variant and find nothing. This happened again and again, and it was rarely misconduct. It was the predictable arithmetic of small samples and many comparisons.

Here is the core trap, stated plainly. If you test enough variables against an outcome, some will cross the threshold for statistical significance by chance alone. Run twenty independent tests at the usual cutoff and, on average, one will look significant when nothing real is there. Genetics confronted this directly and made genome-wide significance thresholds and large replication cohorts the price of entry. A variant was no longer believed because one study saw it. It was believed because it survived in tens of thousands of people across multiple populations. That correction is why the diabetes risk loci we trust today are trustworthy.

The same arithmetic shows up far beyond genetics. In a metabolic study with dozens of biomarkers, in a digital-health dataset with thousands of features, in a trial that quietly measures many endpoints, the danger is identical. The more roads you let yourself walk down, the more likely one ends, by luck, at a publishable result.

What quietly threatens reproducibility?

The threats that worry me most are not dramatic. They are small, reasonable-seeming decisions that bend results without anyone intending harm.

The first is flexibility in analysis, sometimes called the garden of forking paths. A researcher facing real data makes a long series of choices. Which outliers to exclude. Which covariates to adjust for. Where to draw the cutoff between high and low. Each choice can be defensible on its own. Taken together, and steered even unconsciously toward the result you hoped to see, they can manufacture a finding out of noise. The honest researcher who tries five reasonable models and reports the one that worked has not lied. They have simply let the data choose the analysis, which is enough to break reproducibility.

The second is selective reporting. Studies with striking positive results get written up and published faster than studies that found nothing, while the null results sit in a drawer. When the published literature is then summarized, the summary skews toward effects that look larger and more certain than they truly are. That bias is invisible from inside any single paper, which is what makes it dangerous.

A third threat is underpowered design. A study too small to reliably detect the effect it is chasing will, on the rare occasion it hits significance, tend to overstate that effect. Small studies do not just miss real things. When they catch something, they often exaggerate it.

None of this requires a villain. It requires only ordinary incentives and ordinary human hope, which every working scientist carries. Naming the mechanism, rather than blaming the person, is the first step toward fixing it.

What does good practice actually look like?

Pre-registration

The single most powerful tool I know is pre-registration: writing down your hypothesis, your primary outcome, and your analysis plan before you see the data, and depositing that plan somewhere time-stamped and public. Pre-registration does not stop you from exploring. It draws a clean line between the confirmatory test you committed to and the exploratory analyses you ran afterward. Both are valuable. They simply carry different weight, and pre-registration keeps you honest about which is which.

When my colleagues and I ran the EASY-1 randomized controlled trial for our AI clinical decision-support system in type 2 diabetes, the trial carried a registration number (NCT03258268) before patients were enrolled. That registration is not bureaucratic decoration. It is a public commitment that says, in advance, here is what we set out to measure, so that no one later can quietly move the goalposts.

Sharing data and code

A result you cannot inspect is a result you have to take on faith. Sharing de-identified data and the actual analysis code lets others reproduce your numbers exactly, find the bug you missed, and build on your work without starting over. In my systems-medicine work, the premise is that large datasets become more valuable as more capable hands touch them. Sharing is how the field compounds its returns.

Independent replication

Replication is the field's immune system. We treat the established diabetes genetics findings as solid because they have been reproduced in independent cohorts, sometimes across different ancestries. My meta-analysis in Diabetes Care, which examined how the relationship between insulin sensitivity and insulin response differs across ethnic groups, exists because pooling and re-examining many studies tells you something no single study can: whether an effect is consistent, and where it genuinely varies. Heterogeneity across populations is real, and only replication across populations can map it.

How can a reader judge whether a finding is trustworthy?

You do not need a statistics degree to ask good questions. Was the study registered before it began? Is the sample large enough to support its claim? Did an independent group reproduce it, or is this the first and only sighting? Are the data and methods available for others to check? A finding that answers yes has earned more of your confidence than a lone, unregistered, unreplicated headline.

This is educational content about research methods, not medical advice. If anything here touches a decision about your own diabetes care, please talk it through with your own clinician, who knows your history.

The hopeful part

I came up through a field that had its reproducibility reckoning and came out stronger. Diabetes genetics rebuilt its standards, and the payoff was a catalog of findings that hold. The tools that protect reproducibility, pre-registration, open data, honest reporting of nulls, and patient replication, are not exotic. They are habits, and habits spread. Each researcher who adopts them makes the literature a little more solid for everyone who reads it next.